世界のヒト用ベロ細胞狂犬病ワクチン市場インサイト及び予測(フリーズドライ粉末、液体)

◆英語タイトル:Global Vero Cell Rabies Vaccines for Human Market Insights, Forecast to 2028

QYResearchが発行した調査報告書(QY22JLX10518)◆商品コード:QY22JLX10518
◆発行会社(リサーチ会社):QYResearch
◆発行日:2022年7月(※2025年版があります。お問い合わせください。)
◆ページ数:90
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥744,800見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,117,200見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,489,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、ヒト用ベロ細胞狂犬病ワクチンのグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にヒト用ベロ細胞狂犬病ワクチンの世界市場のxxx%を占める「フリーズドライ粉末」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「暴露前予防」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
ヒト用ベロ細胞狂犬病ワクチンの中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパのヒト用ベロ細胞狂犬病ワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

ヒト用ベロ細胞狂犬病ワクチンのグローバル主要企業には、Bharat Biotech、Sanofi-Pasteur、Chengda Bio、Prcmise、Zhuoyi Biological、Ningbo Rongan Biological、Indian Immunologicalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

ヒト用ベロ細胞狂犬病ワクチン市場は、種類と用途によって区分されます。世界のヒト用ベロ細胞狂犬病ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
フリーズドライ粉末、液体

【用途別セグメント】
暴露前予防、暴露後予防

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- ヒト用ベロ細胞狂犬病ワクチン製品概要
- 種類別市場(フリーズドライ粉末、液体)
- 用途別市場(暴露前予防、暴露後予防)
- 調査の目的
・エグゼクティブサマリー
- 世界のヒト用ベロ細胞狂犬病ワクチン販売量予測2017-2028
- 世界のヒト用ベロ細胞狂犬病ワクチン売上予測2017-2028
- ヒト用ベロ細胞狂犬病ワクチンの地域別販売量
- ヒト用ベロ細胞狂犬病ワクチンの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別ヒト用ベロ細胞狂犬病ワクチン販売量
- 主要メーカー別ヒト用ベロ細胞狂犬病ワクチン売上
- 主要メーカー別ヒト用ベロ細胞狂犬病ワクチン価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(フリーズドライ粉末、液体)
- ヒト用ベロ細胞狂犬病ワクチンの種類別販売量
- ヒト用ベロ細胞狂犬病ワクチンの種類別売上
- ヒト用ベロ細胞狂犬病ワクチンの種類別価格
・用途別市場規模(暴露前予防、暴露後予防)
- ヒト用ベロ細胞狂犬病ワクチンの用途別販売量
- ヒト用ベロ細胞狂犬病ワクチンの用途別売上
- ヒト用ベロ細胞狂犬病ワクチンの用途別価格
・北米市場
- 北米のヒト用ベロ細胞狂犬病ワクチン市場規模(種類別、用途別)
- 主要国別のヒト用ベロ細胞狂犬病ワクチン市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのヒト用ベロ細胞狂犬病ワクチン市場規模(種類別、用途別)
- 主要国別のヒト用ベロ細胞狂犬病ワクチン市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のヒト用ベロ細胞狂犬病ワクチン市場規模(種類別、用途別)
- 主要国別のヒト用ベロ細胞狂犬病ワクチン市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のヒト用ベロ細胞狂犬病ワクチン市場規模(種類別、用途別)
- 主要国別のヒト用ベロ細胞狂犬病ワクチン市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのヒト用ベロ細胞狂犬病ワクチン市場規模(種類別、用途別)
- 主要国別のヒト用ベロ細胞狂犬病ワクチン市場規模(トルコ、サウジアラビア)
・企業情報
Bharat Biotech、Sanofi-Pasteur、Chengda Bio、Prcmise、Zhuoyi Biological、Ningbo Rongan Biological、Indian Immunologicals
・産業チェーン及び販売チャネル分析
- ヒト用ベロ細胞狂犬病ワクチンの産業チェーン分析
- ヒト用ベロ細胞狂犬病ワクチンの原材料
- ヒト用ベロ細胞狂犬病ワクチンの生産プロセス
- ヒト用ベロ細胞狂犬病ワクチンの販売及びマーケティング
- ヒト用ベロ細胞狂犬病ワクチンの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- ヒト用ベロ細胞狂犬病ワクチンの産業動向
- ヒト用ベロ細胞狂犬病ワクチンのマーケットドライバー
- ヒト用ベロ細胞狂犬病ワクチンの課題
- ヒト用ベロ細胞狂犬病ワクチンの阻害要因
・主な調査結果

Market Analysis and Insights: Global Vero Cell Rabies Vaccines for Human Market
Due to the COVID-19 pandemic, the global Vero Cell Rabies Vaccines for Human market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Freeze-dried Powder accounting for % of the Vero Cell Rabies Vaccines for Human global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Pre-exposure Prophylaxis segment is altered to an % CAGR throughout this forecast period.
China Vero Cell Rabies Vaccines for Human market size is valued at US$ million in 2021, while the US and Europe Vero Cell Rabies Vaccines for Human are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Vero Cell Rabies Vaccines for Human landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Vero Cell Rabies Vaccines for Human include Bharat Biotech, Sanofi-Pasteur, Chengda Bio, Prcmise, Zhuoyi Biological, Ningbo Rongan Biological and Indian Immunologicals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Vero Cell Rabies Vaccines for Human Scope and Segment
Vero Cell Rabies Vaccines for Human market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Vero Cell Rabies Vaccines for Human market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Freeze-dried Powder
Liquid
Segment by Application
Pre-exposure Prophylaxis
Post-exposure Prophylaxis
By Company
Bharat Biotech
Sanofi-Pasteur
Chengda Bio
Prcmise
Zhuoyi Biological
Ningbo Rongan Biological
Indian Immunologicals
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Vero Cell Rabies Vaccines for Human Product Introduction
1.2 Market by Type
1.2.1 Global Vero Cell Rabies Vaccines for Human Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Freeze-dried Powder
1.2.3 Liquid
1.3 Market by Application
1.3.1 Global Vero Cell Rabies Vaccines for Human Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pre-exposure Prophylaxis
1.3.3 Post-exposure Prophylaxis
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Vero Cell Rabies Vaccines for Human Sales Estimates and Forecasts 2017-2028
2.2 Global Vero Cell Rabies Vaccines for Human Revenue Estimates and Forecasts 2017-2028
2.3 Global Vero Cell Rabies Vaccines for Human Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Vero Cell Rabies Vaccines for Human Sales by Region
2.4.1 Global Vero Cell Rabies Vaccines for Human Sales by Region (2017-2022)
2.4.2 Global Sales Vero Cell Rabies Vaccines for Human by Region (2023-2028)
2.5 Global Vero Cell Rabies Vaccines for Human Revenue by Region
2.5.1 Global Vero Cell Rabies Vaccines for Human Revenue by Region (2017-2022)
2.5.2 Global Vero Cell Rabies Vaccines for Human Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Vero Cell Rabies Vaccines for Human Sales by Manufacturers
3.1.1 Global Top Vero Cell Rabies Vaccines for Human Manufacturers by Sales (2017-2022)
3.1.2 Global Vero Cell Rabies Vaccines for Human Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Vero Cell Rabies Vaccines for Human in 2021
3.2 Global Vero Cell Rabies Vaccines for Human Revenue by Manufacturers
3.2.1 Global Vero Cell Rabies Vaccines for Human Revenue by Manufacturers (2017-2022)
3.2.2 Global Vero Cell Rabies Vaccines for Human Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Vero Cell Rabies Vaccines for Human Revenue in 2021
3.3 Global Vero Cell Rabies Vaccines for Human Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Vero Cell Rabies Vaccines for Human Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Vero Cell Rabies Vaccines for Human Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Vero Cell Rabies Vaccines for Human Sales by Type
4.1.1 Global Vero Cell Rabies Vaccines for Human Historical Sales by Type (2017-2022)
4.1.2 Global Vero Cell Rabies Vaccines for Human Forecasted Sales by Type (2023-2028)
4.1.3 Global Vero Cell Rabies Vaccines for Human Sales Market Share by Type (2017-2028)
4.2 Global Vero Cell Rabies Vaccines for Human Revenue by Type
4.2.1 Global Vero Cell Rabies Vaccines for Human Historical Revenue by Type (2017-2022)
4.2.2 Global Vero Cell Rabies Vaccines for Human Forecasted Revenue by Type (2023-2028)
4.2.3 Global Vero Cell Rabies Vaccines for Human Revenue Market Share by Type (2017-2028)
4.3 Global Vero Cell Rabies Vaccines for Human Price by Type
4.3.1 Global Vero Cell Rabies Vaccines for Human Price by Type (2017-2022)
4.3.2 Global Vero Cell Rabies Vaccines for Human Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Vero Cell Rabies Vaccines for Human Sales by Application
5.1.1 Global Vero Cell Rabies Vaccines for Human Historical Sales by Application (2017-2022)
5.1.2 Global Vero Cell Rabies Vaccines for Human Forecasted Sales by Application (2023-2028)
5.1.3 Global Vero Cell Rabies Vaccines for Human Sales Market Share by Application (2017-2028)
5.2 Global Vero Cell Rabies Vaccines for Human Revenue by Application
5.2.1 Global Vero Cell Rabies Vaccines for Human Historical Revenue by Application (2017-2022)
5.2.2 Global Vero Cell Rabies Vaccines for Human Forecasted Revenue by Application (2023-2028)
5.2.3 Global Vero Cell Rabies Vaccines for Human Revenue Market Share by Application (2017-2028)
5.3 Global Vero Cell Rabies Vaccines for Human Price by Application
5.3.1 Global Vero Cell Rabies Vaccines for Human Price by Application (2017-2022)
5.3.2 Global Vero Cell Rabies Vaccines for Human Price Forecast by Application (2023-2028)
6 North America
6.1 North America Vero Cell Rabies Vaccines for Human Market Size by Type
6.1.1 North America Vero Cell Rabies Vaccines for Human Sales by Type (2017-2028)
6.1.2 North America Vero Cell Rabies Vaccines for Human Revenue by Type (2017-2028)
6.2 North America Vero Cell Rabies Vaccines for Human Market Size by Application
6.2.1 North America Vero Cell Rabies Vaccines for Human Sales by Application (2017-2028)
6.2.2 North America Vero Cell Rabies Vaccines for Human Revenue by Application (2017-2028)
6.3 North America Vero Cell Rabies Vaccines for Human Market Size by Country
6.3.1 North America Vero Cell Rabies Vaccines for Human Sales by Country (2017-2028)
6.3.2 North America Vero Cell Rabies Vaccines for Human Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Vero Cell Rabies Vaccines for Human Market Size by Type
7.1.1 Europe Vero Cell Rabies Vaccines for Human Sales by Type (2017-2028)
7.1.2 Europe Vero Cell Rabies Vaccines for Human Revenue by Type (2017-2028)
7.2 Europe Vero Cell Rabies Vaccines for Human Market Size by Application
7.2.1 Europe Vero Cell Rabies Vaccines for Human Sales by Application (2017-2028)
7.2.2 Europe Vero Cell Rabies Vaccines for Human Revenue by Application (2017-2028)
7.3 Europe Vero Cell Rabies Vaccines for Human Market Size by Country
7.3.1 Europe Vero Cell Rabies Vaccines for Human Sales by Country (2017-2028)
7.3.2 Europe Vero Cell Rabies Vaccines for Human Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Vero Cell Rabies Vaccines for Human Market Size by Type
8.1.1 Asia Pacific Vero Cell Rabies Vaccines for Human Sales by Type (2017-2028)
8.1.2 Asia Pacific Vero Cell Rabies Vaccines for Human Revenue by Type (2017-2028)
8.2 Asia Pacific Vero Cell Rabies Vaccines for Human Market Size by Application
8.2.1 Asia Pacific Vero Cell Rabies Vaccines for Human Sales by Application (2017-2028)
8.2.2 Asia Pacific Vero Cell Rabies Vaccines for Human Revenue by Application (2017-2028)
8.3 Asia Pacific Vero Cell Rabies Vaccines for Human Market Size by Region
8.3.1 Asia Pacific Vero Cell Rabies Vaccines for Human Sales by Region (2017-2028)
8.3.2 Asia Pacific Vero Cell Rabies Vaccines for Human Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Vero Cell Rabies Vaccines for Human Market Size by Type
9.1.1 Latin America Vero Cell Rabies Vaccines for Human Sales by Type (2017-2028)
9.1.2 Latin America Vero Cell Rabies Vaccines for Human Revenue by Type (2017-2028)
9.2 Latin America Vero Cell Rabies Vaccines for Human Market Size by Application
9.2.1 Latin America Vero Cell Rabies Vaccines for Human Sales by Application (2017-2028)
9.2.2 Latin America Vero Cell Rabies Vaccines for Human Revenue by Application (2017-2028)
9.3 Latin America Vero Cell Rabies Vaccines for Human Market Size by Country
9.3.1 Latin America Vero Cell Rabies Vaccines for Human Sales by Country (2017-2028)
9.3.2 Latin America Vero Cell Rabies Vaccines for Human Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Vero Cell Rabies Vaccines for Human Market Size by Type
10.1.1 Middle East and Africa Vero Cell Rabies Vaccines for Human Sales by Type (2017-2028)
10.1.2 Middle East and Africa Vero Cell Rabies Vaccines for Human Revenue by Type (2017-2028)
10.2 Middle East and Africa Vero Cell Rabies Vaccines for Human Market Size by Application
10.2.1 Middle East and Africa Vero Cell Rabies Vaccines for Human Sales by Application (2017-2028)
10.2.2 Middle East and Africa Vero Cell Rabies Vaccines for Human Revenue by Application (2017-2028)
10.3 Middle East and Africa Vero Cell Rabies Vaccines for Human Market Size by Country
10.3.1 Middle East and Africa Vero Cell Rabies Vaccines for Human Sales by Country (2017-2028)
10.3.2 Middle East and Africa Vero Cell Rabies Vaccines for Human Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bharat Biotech
11.1.1 Bharat Biotech Corporation Information
11.1.2 Bharat Biotech Overview
11.1.3 Bharat Biotech Vero Cell Rabies Vaccines for Human Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bharat Biotech Vero Cell Rabies Vaccines for Human Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bharat Biotech Recent Developments
11.2 Sanofi-Pasteur
11.2.1 Sanofi-Pasteur Corporation Information
11.2.2 Sanofi-Pasteur Overview
11.2.3 Sanofi-Pasteur Vero Cell Rabies Vaccines for Human Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Sanofi-Pasteur Vero Cell Rabies Vaccines for Human Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi-Pasteur Recent Developments
11.3 Chengda Bio
11.3.1 Chengda Bio Corporation Information
11.3.2 Chengda Bio Overview
11.3.3 Chengda Bio Vero Cell Rabies Vaccines for Human Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Chengda Bio Vero Cell Rabies Vaccines for Human Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Chengda Bio Recent Developments
11.4 Prcmise
11.4.1 Prcmise Corporation Information
11.4.2 Prcmise Overview
11.4.3 Prcmise Vero Cell Rabies Vaccines for Human Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Prcmise Vero Cell Rabies Vaccines for Human Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Prcmise Recent Developments
11.5 Zhuoyi Biological
11.5.1 Zhuoyi Biological Corporation Information
11.5.2 Zhuoyi Biological Overview
11.5.3 Zhuoyi Biological Vero Cell Rabies Vaccines for Human Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Zhuoyi Biological Vero Cell Rabies Vaccines for Human Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Zhuoyi Biological Recent Developments
11.6 Ningbo Rongan Biological
11.6.1 Ningbo Rongan Biological Corporation Information
11.6.2 Ningbo Rongan Biological Overview
11.6.3 Ningbo Rongan Biological Vero Cell Rabies Vaccines for Human Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Ningbo Rongan Biological Vero Cell Rabies Vaccines for Human Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Ningbo Rongan Biological Recent Developments
11.7 Indian Immunologicals
11.7.1 Indian Immunologicals Corporation Information
11.7.2 Indian Immunologicals Overview
11.7.3 Indian Immunologicals Vero Cell Rabies Vaccines for Human Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Indian Immunologicals Vero Cell Rabies Vaccines for Human Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Indian Immunologicals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Vero Cell Rabies Vaccines for Human Industry Chain Analysis
12.2 Vero Cell Rabies Vaccines for Human Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vero Cell Rabies Vaccines for Human Production Mode & Process
12.4 Vero Cell Rabies Vaccines for Human Sales and Marketing
12.4.1 Vero Cell Rabies Vaccines for Human Sales Channels
12.4.2 Vero Cell Rabies Vaccines for Human Distributors
12.5 Vero Cell Rabies Vaccines for Human Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Vero Cell Rabies Vaccines for Human Industry Trends
13.2 Vero Cell Rabies Vaccines for Human Market Drivers
13.3 Vero Cell Rabies Vaccines for Human Market Challenges
13.4 Vero Cell Rabies Vaccines for Human Market Restraints
14 Key Findings in The Global Vero Cell Rabies Vaccines for Human Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のヒト用ベロ細胞狂犬病ワクチン市場インサイト及び予測(フリーズドライ粉末、液体)(Global Vero Cell Rabies Vaccines for Human Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。